June 11, 2025
The Federal Circuit on Wednesday affirmed Patent Trial and Appeal Board decisions finding every claim invalid in two Agilent Technologies patents on the gene-editing tool CRISPR, sealing a win for Synthego Corp., which has been accused of infringing them.
May 17, 2023
The Patent Trial and Appeal Board found Wednesday that two Agilent Technologies Inc. patents on the gene-editing tool CRISPR were invalid, the latest dustup in a legal fight brought by Synthego Corp. over the breakthrough technology.